IBL Healthcare invests in KNISS Laboratories

KNISS has established a solid foundation of trust in the customers' minds, delivering high quality Products uncompromisingly.

Lynparza plus abi/pred approved in Japan for treatment of prostate cancer

First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent

Intuitive and Max Healthcare to launch TPO Centre for robotic-assisted surgery

Centre aims to train surgeons and other healthcare professionals from India and Southeast Asia in robotic-assisted surgery

Glenmark Pharmaceuticals USA reaches antitrust settlement with DOJ

The company has entered into a three-year Deferred Prosecution Agreement

LEO Pharma to acquire Timber Pharmaceuticals

The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million

EMA accepts LEO Pharma’s MAA for delgocitinib cream in chronic hand eczema

LEO Pharma is developing delgocitinib cream for the treatment of moderate to severe chronic hand eczema, a hard-to-treat disease where there is a high unmet medical need for treatment

Venus Remedies launches its flagship R&D drug Elores in Oman

The antibacterial market in Oman is worth US $7.5 million, and Elores is looking to capture 0.5 per cent of this segment by year 2025

Lupin acquires Boehringer Ingelheim's brands Ondero and Ondero Met to expand diabetes portfolio in India

This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes

Hikal receives Brazilian GMP certification and USFDA EIR for Bangalore and Panoli facilities

Lupin's Mandideep Unit-2 facility completes USFDA inspection with no observations

The inspection was conducted from August 7 to August 11, 2023 and concluded without any observations.